Pharma startup Bonti has recently grabbed a funding of USD 15 million
Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the development of company’s lead drug, EB-001 and in other market research activities.
NIH to boost up the gene editing development process by putting USD 190 million
Recently, the Gene-editing techniques such as CRISPR-Cas9 has grabbed a lot of attention after showing some promising results and are already transforming research. But there is still a long way ...
